Comment

  • 6 April 2018

    Vaccine development: the need for speed

    When responding to outbreaks of viral disease, public health officials are often challenged to reconcile the rapid and unpredictable nature of emerging infections with the plodding pace of vaccine development.

  • 23 March 2018

    Is IL-23 the new hot target for Psoriasis?

    On March 21, the FDA approved Sun Pharma’s Ilumya (tildrakizumab) for the treatment of adults with moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy....